Scholar Rock to Present New Apitegromab Data Including 24-Month Efficacy and Safety Data from TOPAZ Phase 2 Trial at the 2022 Annual Cure SMA Conference

Via Peters

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company will deliver two podium presentations on 24-month data from the TOPAZ Phase 2 clinical trial at the 2022 SMA […]

A systematic review and meta-analysis of population-based studies including over 80 million births

Via Peters

Citation: Zhang T-N, Huang X-M, Zhao X-Y, Wang W, Wen R, Gao S-Y (2022) Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births. PLoS Med 19(2): e1003900. https://doi.org/10.1371/journal.pmed.1003900 Academic Editor: Jenny E. Myers, University of […]